Recognizing Endocrine Disorders: A Required Skill Set for Immuno-Oncology

Endocrine dysfunction was more common in patients receiving combination therapy versus monotherapy.

The integration of immune checkpoint inhibitors (ICIs) into standard care for several malignancies is forcing oncologists to consider the diagnosis and management of endocrinopathies associated with these agents.

To examine the incidence of endocrine dysfunction in cancer patients receiving ICIs and risks for endocrine dysfunction associated with different ICI regimens, investigators conducted a meta-analysis of 38 randomized trials involving 7551 patients with advanced solid tumors. Patients were treated with one of four ICI regimens: monotherapy with a PD-1 inhibitor (nivolumab or pembrolizumab), a CTLA-4 inhibitor (ipilimumab), or a PD-L1 inhibitor (atezolizumab); or combination therapy with a PD-1 and CTLA-4 inhibitor. The primary outcom…

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)